Sudan Loganathan
Stock Analyst at Stephens & Co.
(1.10)
# 3,762
Out of 4,984 analysts
34
Total ratings
37.04%
Success rate
-13.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Upgrades: Overweight | $3 → $6 | $3.38 | +77.51% | 2 | Sep 15, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $24.44 | +84.12% | 3 | Sep 9, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $8.57 | +250.06% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $40.44 | +48.37% | 5 | Jun 24, 2025 | |
| DCTH Delcath Systems | Reiterates: Overweight | $25 | $11.20 | +123.21% | 3 | Jun 23, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $8.99 | +233.70% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $20.02 | +64.84% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $3.25 | +146.15% | 2 | Feb 24, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $6.92 | +116.76% | 2 | Jan 22, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $48.12 | +24.69% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.61 | +210.56% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $7.61 | +622.73% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $2.21 | +488.24% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $9.00 | +1,011.11% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.18 | +817.43% | 1 | May 14, 2024 |
C4 Therapeutics
Sep 15, 2025
Upgrades: Overweight
Price Target: $3 → $6
Current: $3.38
Upside: +77.51%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $24.44
Upside: +84.12%
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $8.57
Upside: +250.06%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $40.44
Upside: +48.37%
Delcath Systems
Jun 23, 2025
Reiterates: Overweight
Price Target: $25
Current: $11.20
Upside: +123.21%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $8.99
Upside: +233.70%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $20.02
Upside: +64.84%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.25
Upside: +146.15%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $6.92
Upside: +116.76%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $48.12
Upside: +24.69%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.61
Upside: +210.56%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $7.61
Upside: +622.73%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $2.21
Upside: +488.24%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $9.00
Upside: +1,011.11%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.18
Upside: +817.43%